NASDAQ: GRNAGreenlight Biosciences Holdings PBC Stock
$0.29+0.00 (+0%)
Updated Jun 5, 2023
GRNA Price
$0.29
Fair Value Price
$0.81
Market Cap
$44.44M
52 Week Low
$0.18
52 Week High
$6.91
P/E
-0.26x
P/B
2.03x
P/S
6.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.34M
Earnings
-$157.32M
Gross Margin
100%
Operating Margin
-1,471.22%
Profit Margin
-1,521%
Debt to Equity
4.18
Operating Cash Flow
-$118M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRNA Overview
GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRNA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRNA ($0.29) is undervalued by 63.83% relative to our estimate of its Fair Value price of $0.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GRNA ($0.29) is significantly undervalued by 63.83% relative to our estimate of its Fair Value price of $0.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
GRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GRNA due diligence checks available for Premium users.
Be the first to know about important GRNA news, forecast changes, insider trades & much more!
GRNA News
Valuation
GRNA fair value
Fair Value of GRNA stock based on Discounted Cash Flow (DCF)
Price
$0.29
Fair Value
$0.81
Undervalued by
64.20%
GRNA ($0.29) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRNA ($0.29) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRNA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRNA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
11.59x
Market
53.21x
GRNA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.03x
Industry
5.21x
GRNA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRNA's financial health
Profit margin
Revenue
$3.8M
Net Income
-$28.5M
Profit Margin
-745.3%
GRNA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GRNA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$113.7M
Liabilities
$91.8M
Debt to equity
4.18
GRNA's short-term assets ($37.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRNA's long-term liabilities ($60.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRNA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.1M
Investing
-$1.6M
Financing
-$3.0M
GRNA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRNA vs Biotech Stocks
Greenlight Biosciences Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.